Bausch Health/$BHC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
- Ticker
- $BHC
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,300
- Headquarters
- Laval, Canada
- Website
- www.bauschhealth.com
Bausch Health Metrics
BasicAdvanced
$3B
-
-$2.25
0.37
-
Price and volume
Market cap
$3B
Beta
0.37
52-week high
$9.04
52-week low
$4.33
Average daily volume
3.4M
Financial strength
Current ratio
1.56
Quick ratio
1.057
Long term debt to equity
-58.158
Total debt to equity
-60.748
Interest coverage (TTM)
1.89%
Profitability
EBITDA (TTM)
4,166
Gross margin (TTM)
72.06%
Net profit margin (TTM)
-7.57%
Operating margin (TTM)
27.14%
Effective tax rate (TTM)
-134.56%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
7.22%
Return on equity (TTM)
-11,040.00%
Valuation
Price to revenue (TTM)
0.27
Price to book
-2.26
Price to tangible book (TTM)
-0.2
Price to free cash flow (TTM)
1.641
Free cash flow yield (TTM)
60.94%
Free cash flow per share (TTM)
4.887
Growth
Revenue change (TTM)
10.81%
Earnings per share change (TTM)
-332.48%
3-year revenue growth (CAGR)
9.17%
10-year revenue growth (CAGR)
1.04%
3-year earnings per share growth (CAGR)
-5.23%
10-year earnings per share growth (CAGR)
-10.15%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Analyst projections of the future price of Bausch Health stock.
Bulls say / Bears say
Bausch Health is showing durable operating momentum: third-quarter revenue rose 10% (8% organically), and management raised its 2026 revenue, adjusted EBITDA and cash-flow guidance after the fourteenth consecutive quarter of growth in the business excluding Bausch + Lomb. (SEC)
Bausch + Lomb, Bausch Health’s major eye-health business, grew third-quarter revenue 7% with gains across all three segments and raised its full-year outlook. Fast-growing MIEBO, daily contact lenses and premium intraocular lenses provide clear growth drivers. (SEC)
Cash generation is helping repair the balance sheet: Bausch Health reported $813 million of third-quarter operating cash flow and more than $500 million of quarterly net-debt reduction. Recent refinancing also improved its debt maturity profile. (SEC)
Bausch Health still carries about $20.2 billion of debt against $2.5 billion of cash, with $3.8 billion of principal maturities in 2028. The company’s ability to reduce this burden relies on sustaining strong cash generation. (SEC)
Xifaxan faces lower US Medicare pricing from 2027. Management said the related channel-accrual changes and inventory normalisation will materially weigh on fourth-quarter revenue and earnings growth. (The Motley Fool)
Generic manufacturers are challenging Xifaxan’s patents, and mediation failed to settle the dispute. An adverse outcome could bring generic competition sooner and weaken a key source of revenue. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bausch Health News
AllArticlesVideos
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
MarketBeat5 days ago
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Business Wire3 weeks ago
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Business Wire2 months ago
Funds containing Bausch Health
AllUSDEURGBP
Fund name | Fund size | $BHC weighting |
|---|---|---|
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.02% |
Vanguard ESG North America All Cap$V3NA | $290M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.